LP 143
Alternative Names: AN143; LP143Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Longboard Pharmaceuticals
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Parkinson's disease
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (PO)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO)
- 02 Dec 2024 Longboard Pharmaceuticals has been acquired by Lundbeck A/S